{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:55Z","timestamp":1776988795628,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"GlaxoSmith Kline"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clgc.2016.03.011","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T17:46:56Z","timestamp":1457804816000},"page":"432-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Sujata","family":"Narayanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Harshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Pachynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shermeen","family":"Poushnejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.03.011_bib1","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2016.03.011_bib2","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib3","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2002.20.4.937","article-title":"Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer","volume":"20","author":"Vaughn","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1470-2045(13)70162-1","article-title":"Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study","volume":"14","author":"Ko","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib7","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/jnci\/87.21.1603","article-title":"Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis","volume":"87","author":"Bochner","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.03.011_bib8","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/sj.onc.1206285","article-title":"VEGF receptor expression and signaling in human bladder tumors","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.clgc.2016.03.011_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2016.03.011_bib10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1470-2045(12)70294-2","article-title":"Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial","volume":"13","author":"Necchi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1634\/theoncologist.2010-0095","article-title":"Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2016.03.011_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib13","series-title":"Stata Statistical Software: Release 11","author":"StataCorp","year":"2009"},{"key":"10.1016\/j.clgc.2016.03.011_bib14","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2012.11.042","article-title":"Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials","volume":"63","author":"Sonpavde","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.03.011_bib16","first-page":"47","article-title":"Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma\u2014prognostic factors for response and improvement of quality of life","volume":"25","author":"Albers","year":"2002","journal-title":"Onkologie"},{"key":"10.1016\/j.clgc.2016.03.011_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A\u00a0phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.bjc.6603118","article-title":"A\u00a0phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen","volume":"94","author":"Culine","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib19","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1002\/cncr.24460","article-title":"Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study","volume":"115","author":"Vaughn","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib20","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib21","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2005.03.6699","article-title":"Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium","volume":"24","author":"Sweeney","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib22","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2001.19.12.3018","article-title":"Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"19","author":"Meluch","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib23","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2","article-title":"Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy","volume":"92","author":"Sternberg","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<514::AID-CNCR21>3.0.CO;2-9","article-title":"A\u00a0phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium","volume":"86","author":"Sweeney","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib25","first-page":"67","article-title":"Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study","volume":"165","author":"Krege","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.03.011_bib26","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1200\/JCO.2002.11.114","article-title":"Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma","volume":"20","author":"Pagliaro","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/cncr.21370","article-title":"Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study","volume":"104","author":"Vaishampayan","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1023\/A:1012599307090","article-title":"Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer: a phase II trial conducted by the Hellenic Cooperative Oncology Group","volume":"12","author":"Pectasides","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2011.37.7002","article-title":"Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer","volume":"30","author":"Choueiri","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib30","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2009.25.3922","article-title":"Phase II study of sunitinib in patients with metastatic urothelial cancer","volume":"28","author":"Gallagher","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib31","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1002\/cncr.24467","article-title":"Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group","volume":"115","author":"Dreicer","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.urology.2010.04.025","article-title":"Phase II study of aflibercept (VEGF-TRAP) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial","volume":"76","author":"Twardowski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2016.03.011_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clgc.2013.05.005","article-title":"A\u00a0phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer","volume":"11","author":"Pili","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib34","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2012.41.9572","article-title":"Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma","volume":"30","author":"Wong","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.03.011_bib35","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","article-title":"A\u00a0single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma","volume":"115","author":"Wulfing","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.03.011_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1464-410X.2009.08799.x","article-title":"Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium","volume":"105","author":"Petrylak","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2016.03.011_bib37","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2016.03.011_bib38","article-title":"Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma","volume":"33","author":"Petrylak","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316300659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316300659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:43Z","timestamp":1761564343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316300659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1558767316300659"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.03.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}